NCT02242825已完成不适用
Micardis® / MicardisPlus® Monitoring of Morning Hypertension and Metabolism II
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 8,148
- 主要终点
- Change from Baseline in systolic blood pressure (SBP)
研究概览
简要总结
The primary objective is to evaluate the effect of the treatment with Micardis® or MicardisPlus® on blood pressure. Secondary objectives are the effect of Micardis® / MicardisPlus® on metabolic parameters (triglycerides, cholesterol, blood glucose and HbA1c) in patients with essential hypertension and diabetes mellitus
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years
- •Hypertension
- •Diabetes mellitus
排除标准
- •Age < 18 years
研究组 & 干预措施
Patients with hypertension and diabetes mellitus
干预措施: MicardisPlus® (Drug)
Patients with hypertension and diabetes mellitus
干预措施: Micardis® (Drug)
结局指标
主要结局
Change from Baseline in systolic blood pressure (SBP)
时间窗: Baseline, after 6 months
Change from Baseline in diastolic blood pressure (DBP)
时间窗: Baseline, afterr 6 months
次要结局
- Assessment of metabolic effect on a 4-point scale(after 6 months)
- Assessment of efficacy by investigator on a 6-point scale(after 6 months)
- Assessment of tolerability by investigator on a 5-point scale(after 6 months)
- Change from Baseline in laboratory parameters(Baseline, after 6 months)
- Number of patients with adverse events(up to 6 months)
研究者
相似试验
已完成
不适用
Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood PressureHypertensionNCT02242864Boehringer Ingelheim1,527
已完成
不适用
Micardis®. Observational Study in Patients With Essential HypertensionHypertensionNCT02200094Boehringer Ingelheim4,532
已完成
不适用
Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With HypertensionHypertensionNCT02242383Boehringer Ingelheim13,248
已完成
不适用
Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)HypertensionNCT02262637Boehringer Ingelheim4,814
已完成
不适用
Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With HypertensionHypertensionNCT02242357Boehringer Ingelheim14,553